Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending ...

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. The breakup came after Novo raised concerns about Hims selling ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.